Filter Lifespan in Continuous Renal Replacement Therapy

Sponsor
University Hospital Muenster
Study ID
NCT05450185
Status
Recruiting
Apply to this trial

Conditions

  • Continuous Renal Replacement Therapy
  • Critically Ill
  • Infections

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Critically ill patients with continuous renal replacement therapy — PROCEDURE
    Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.

Study Details

The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.

Key Dates

First listed
Jul 8, 2022
Start date
Mar 2, 2023
Status verified
Dec 2024
Primary completion
May 31, 2025
Completion
Aug 31, 2025

Study Design

Enrollment
600 participants (estimated)

Primary Outcome Measure

Number of new infections since start of dialysis [ Time Frame: From start of dialysis until day 28 ]

Central Contacts

  • Alexander Zarbock, MD
    +49-251-8347252
    [email protected]
  • Melanie Meersch-Dini, MD
    +49-251-47255

Related Studies